La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
Si tienes tos, puedes tener una enfermedad respiratoria:
Puede ser COVID-19, si es de aparición rápida, acompañada de tos seca, malestar general, fiebre y dificultad para respirar.
Puede ser TB, si se presenta como una tos de dos o más semanas de duración, y está acompañada de expectora...ción.
more
Informe
Bogotá, 13-14 de abril del 2015
Un cuento para explicarles a los más chicos lo que está pasando.
Escrito por Lic. Guadalupe del Canto,
Psicológa perinatal y especialista en desafíos reproductivos.
El Colegio Oficial de la Psicología de Madrid se caracteriza por la promoción del bienestar de nuestra y por el compromiso de la psicología para alcanzar este fin. Por ello, de manera inmediata, respondiendo a la necesidad y demanda social, se han llevado a cabo una serie de iniciativas orientada...s a promover un afrontamiento adecuado frente al brote de Coronavirus (COVID-19).
more
La OIT ha unido fuerzas con Gallup para llevar a cabo una innovadora encuesta mundial que abarca 50 países y que arroja más luz sobre las causas de la persistencia del estigma y la discriminación relacionados con el VIH en el mundo del trabajo.
The Cost of Security Risk Management for NGOs explores the costs related to safety and security management for aid programmes. It aims to assist all aid practitioners to determine their risk management expenditure more accurately, and demonstrate an evidence-based approach when presenting this infor...mation to donors.
The paper will be particularly relevant to those responsible for programme planning and management, donor proposal writing, as well as safety and security risk management.
more
This document puts forward the joint position and vision of an expert, global, multistakeholder working group on implementing Kangaroo Mother Care (KMC) for all preterm or low birth weight (LBW) infants as the foundation for small and/or sick newborn care within maternal, newborn, and child health p...rogrammes, and spur collaborative global action. The document summarizes the background information, evidence, and rationale for making KMC available to every preterm or LBW newborn and seeks to galvanize the international maternal, newborn, and child health community and families to come together to support the implementation of KMC for all preterm or LBW infants to improve their and their mothers and families health and well-being.
This position paper is intended to be used by policy-makers (i.e. those responsible for national policy, guideline development and budget allocation), development partners, programme managers, health workforce leadership, practising clinicians, civil society leadership (e.g. parent and professional organizations) and researchers/research organizations involved in KMC implementation research.
more
This user guide is designed to provide national malaria control programmes with general information on glucose-6-phosphate dehydrogenase (G6PD) deficiency. Individuals with this condition may be at risk of adverse effects from medicines commonly used to cure Plasmodium vivax malaria, as well as from... other medicines and substances.
more
This Mpox SPRP Global Monitoring & Evaluation (M&E) Framework, also referred to as the Framework, aims to monitor and report on global progress towards these objectives, including information about country-level response efforts and WHO support to Member States. Regular collection and analysis of da...ta on these objectives, alongside the ongoing tracking of the epidemiological situation, are key to informing decision-making, operational adjustments, as well as ensuring transparency and accountability for achieving the goal to stop the Mpox outbreak. This document suggests reporting indicators for monitoring of the global response to the Mpox PHEIC as articulated in the Mpox SPRP and Operational Planning Guidelines for countries.
more
Skin and mucosal conditions are extremely common in all children and adults in particular in HIV-infected adults and children and are one of the commonest daily management problems faced by health care workers caring for patients with HIV infection